Dostarlimab

[MSHL] Dostarlimab Vial 500 mg

1. Monotherapy for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for recurrent or advanced MSI-H or dMMR endometrial cancer.

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

17/02/2025 Dostarlimab for treating dMMR or MSI-H primary advanced or recurrent endometrial cancer

The Ministry of Health’s Drug Advisory Committee has recommended:

• Dostarlimab 500 mg concentrate for solution for infusion, in combination with carboplatin and paclitaxel, followed by dostarlimab as monotherapy for untreated mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. Treatment with dostarlimab should be stopped at 3 years, or earlier if disease progresses.

Funding status

[R] Dostarlimab 500 mg concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2025.

Clinical indication, subsidy class and MediShield Life claim limit for dostarlimab are provided in the Annex.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration